Immunotech Laboratories, Inc.
OTC: IMMB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jennifer L. Bath
- Employees
- 4
- Headquarters
- Monrovia, United States
- IPO year
- 2001
- Market cap
- $115.0K
- Website
- https://www.immunotechlab.com
Loading IMMB…
Loading profile data…Frequently asked questions about IMMB
What does Immunotech Laboratories, Inc. (IMMB) do?
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in...
Where does IMMB trade?
Immunotech Laboratories, Inc. (IMMB) trades on the Other OTC.
What sector is IMMB in?
Immunotech Laboratories, Inc. (IMMB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immunotech Laboratories, Inc.?
Jennifer L. Bath is the chief executive officer of Immunotech Laboratories, Inc. (IMMB).
Where is Immunotech Laboratories, Inc. headquartered?
Immunotech Laboratories, Inc. is headquartered in United States.
Does IMMB pay a dividend?
Immunotech Laboratories, Inc. (IMMB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMMB go public?
Immunotech Laboratories, Inc. (IMMB) completed its initial public offering in 2001.